Key Highlights

  • GeneDx shares closed down 9.73% at $63.39 on Oct. 16, 2026.
  • The GUARDIAN newborn screening study has now enrolled 30,000 newborns.
  • 72.3% of the families approached chose to enroll in the study.
  • Second-quarter revenue reached $114.4 million, with exome and genome volume up 32%.
  • Full-year 2026 revenue guidance stands at $475 million to $490 million.

Shares Retreat From a Recent Rally Despite Newborn Screening Momentum

GeneDx (NASDAQ:WGS) closed down 9.73% at $63.39 on Oct. 16, 2026, as the stock gave back part of its recent gains. Market commentary pointed to profit-taking and company-specific volatility rather than weakness across the wider group, which was holding up better.

The decline came even though sell-side price targets remain bullish and investor attention on the company's genomic newborn screening and pediatric testing efforts has continued.

GeneDx specializes in whole exome and genome sequencing to diagnose pediatric and rare diseases. It also provides data and information services to biopharma and health system partners, and it develops an AI-based platform for sequencing analysis, interpretation and clinical reporting, which expanded through the Fabric Genomics acquisition.

New GUARDIAN Data Highlights Participation and Clinical Findings

Earlier this month, the company presented new findings from the GUARDIAN study at the International Consortium on Newborn Sequencing meeting in Boston. The study has now enrolled 30,000 newborns, and 72.3% of the families approached chose to take part. About 76% of participating newborns represent non-European genetic ancestry, and screen-positive rates were relatively consistent across ancestries once G6PD deficiency cases were excluded.

Genomic screening identified conditions that standard newborn screening missed, including hearing loss in infants who had passed their initial hearing test and Long QT syndrome, a cardiac conduction disorder linked to life-threatening arrhythmias. Among infants diagnosed with Long QT syndrome, eight have started beta-blocker therapy, and cascade testing led six parents and one older sibling to begin preventive treatment. Standard screening also caught select cases that genomic screening missed, which the company said shows the two approaches complement each other.

The NIH-funded BRIDGES-NBS program, where GeneDx is a sequencing partner, will begin enrolling this month with a panel of 746 genes covering 777 genetic conditions that are treatable in the first year of life. The program is expected to expand across eight states and territories. GeneDx is also among the first industry partners supporting Florida's Sunshine Genetics program.

Revenue Growth and Valuation Frame the Pullback

In the second quarter of 2026, GeneDx reported revenue of $114.4 million, exome and genome volume growth of 32% and an adjusted gross margin of 70%. Management reiterated full-year 2026 revenue guidance of $475 million to $490 million, following a first-quarter revenue miss.

The stock carries a market capitalization of about $1.89 billion, a forward price-to-earnings ratio of 73.28 and earnings per share of $0.36. Shares sit within a 52-week range of $32.21 to $170.87, so even after the decline they trade well above the low end of that band.

Outlook: Guidance Delivery and Screening Rollouts Draw Focus

The pullback leaves attention on whether management can deliver within its full-year guidance range and how quickly newborn screening programs such as BRIDGES-NBS and the Florida effort translate into testing volume. The next quarterly report will be the main data point for both.